Clinical aspects and pathophysiological mechanisms of (systemic) right ventricular failure
Zandstra, T.E.

Citation

Version: Publisher's Version
License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden
Downloaded from: https://hdl.handle.net/1887/3628226

Note: To cite this publication please use the final published version (if applicable).
Chapter 8
Potential of eHealth smart technology in optimization and monitoring of heart failure treatment in adults with systemic right ventricular failure

Published in European Heart Journal – Digital Health, 2021

Abstract

Aims

Patients with a systemic right ventricle (sRV) in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected TGA are prone to heart failure and arrhythmias. This study evaluated feasibility, patient adherence, and satisfaction of a smart technology-based care pathway for heart failure treatment optimization in these patients.

Methods and results

Patients with symptomatic sRV failure eligible for initiation of sacubitril/valsartan were provided with four smartphone compatible devices (blood pressure monitor, weight scale, step counter, and rhythm monitor) and were managed according to a smart technology-based care pathway. Biweekly sacubitril/valsartan titration visits were replaced by electronical visits, patients were advised to continue measurements at least weekly after titration. Data of 24 consecutive sRV patients (median age 47 years, 50% female) who participated in the smart technology-based care pathway were analysed. Median home-hospital distance was 65 km (maximum 227 km). Most patients (20, 83.3%) submitted weekly measurements; 100% submitted prior to electronical visits. Titration conventionally occurs during a hospital visit. By implementing eHealth smart technology, 68 such trips to hospital were replaced by virtual visits facilitated by remote monitoring. An eHealth questionnaire was completed by 22 patients (92%), and 96% expressed satisfaction. After titration, 30 instances of remote adjustment of heart failure medication in addition to scheduled outpatient clinic visits occurred, one (4%) heart failure admission followed, despite ambulant adjustments. Five patients (21%) sent in rhythm registrations (n = 17), of these 77% showed sinus rhythm, whereas supraventricular tachycardia was detected in the remaining four registrations.

Conclusion

These data suggest that implementation of a smart technology-based care pathway for optimization of medical treatment sRV failure is feasible with high measurement adherence and patient satisfaction.
Introduction

The number of patients with congenital heart disease (CHD) is growing, with currently over 90% survival to adulthood. Despite the improved surgical outcomes, these patients remain at risk for long-term complications such as heart failure, arrhythmias, and pulmonary hypertension and require lifelong follow-up. In the 21st century, there has been a significant rise in the development and implementation of telemonitoring with smart technology devices and eHealth. The use of telemonitoring via smart technology has shown conflicting results in patients with acquired heart disease, especially in terms of reducing mortality and hospitalizations, yet studies in adult CHD have been carefully optimistic.

The adult CHD population seems particularly eligible for smart technology since they are generally younger than the average cardiac patient, are more likely to be in the possession of a smartphone device, and have a high degree of digital literacy. Previous studies have also shown that they are highly motivated for telemonitoring and eHealth. Care for these patients requires a high degree of specialization and structural follow-up in an expertise centre is indicated for patients with heart failure in the context of CHD. The concentration of care in these tertiary centres often leads to longer travel time and interference with daily (work-) obligations for patients. In addition, patients with CHD have shown to have high utilization of emergency care resources. These factors could make this population particularly fit for telemonitoring via smart technology.

Patients with a systemic right ventricle (sRV)—a morphological right ventricle in a subaortic position supporting the systemic circulation—in the context of transposition of the great arteries (TGA) after atrial switch or congenitally corrected TGA are particularly prone to long-term complications, including sRV heart failure and arrhythmias. Although there are no specific recommendations in the current guidelines for the use of heart failure medication in this population, it is carefully and pragmatically prescribed in sRV failure based on expert opinion, small trials, and lack of alternatives. A recent analysis of 150 adult atrial switch patients in the Netherlands showed decreased mortality in symptomatic patients treated with renin–angiotensin–aldosterone system (RAAS) inhibitors and β-blockers and beneficial effects of sacubitril/valsartan treatment in adults with sRV failure on N-terminal prohormone of brain natriuretic peptide (NT-proBNP) and echocardiographic function have recently been reported. The aim of the current study was to evaluate the feasibility, patient adherence, and appreciation of a smart technology-based care pathway for heart failure treatment optimization and monitoring in sRV failure. The secondary outcome...
of this study was to evaluate the potential of the smart technology-based care in detection of arrhythmias in this group.

Methods
Design and inclusion/exclusion criteria
In this single-centre, non-blinded cohort study performed at the Department of Cardiology at the Leiden University Medical Center, data on all adult patients with a failing sRV in a biventricular circulation who were started on sacubitril/valsartan according to the smart technology-based care pathway in February 2019—February 2020, were reported. Patients who had an (estimated) sRV ejection fraction of ≤40% and had persisting symptomatic heart failure (NYHA class ≥ II) despite treatment with highest tolerated doses of a β-blocker and/or an angiotensin-converting enzyme inhibitor/angiotensin II receptor-blocker for a period of at least 3 months were advised to start treatment with sacubitril/valsartan.17 Patients who were started on sacubitril/valsartan (n=25) were offered four smartphone compatible devices (blood pressure monitor, weight scale, step counter, and rhythm monitor). If they accepted (n=24), they were treated and monitored according to a smart technology-based care pathway (Figure 1). One patient declined participation in digital monitoring due to personal preference for face-to-face meetings with the cardiologist in the outpatient clinic. The conventional pathway consisted of a biweekly visit to the outpatient clinic with either the treating cardiologist or physician assistant specialized in heart failure. Check-up consisted of assessment of complaints, physical examination including blood pressure and weight monitoring and laboratory workup. The smart technology-based pathway was designed based on the previously validated care pathway in post-myocardial infarction patients and consisted of measurements performed by the patients twice a week with the blood pressure monitor and weight scale and biweekly (every 2nd week) consultations by telephone, including assessment of complaints, smart technology measurements, and laboratory workup.18 Patients were instructed to perform laboratory workup at their general practitioner and to perform the above measurements and a single-lead electrocardiogram (ECG) registration in case of complaints of palpitations (Figure 1). Patients were stimulated to use the step counter daily.
Figure 1: Sacubitril/valsartan titration according to the smart technology care pathway.
BP, blood pressure; ccTGA, congenitally corrected transposition of the great arteries;
GP, general practitioner; HF, heart failure; OMT, optimal medical treatment; RV, right ventricle; TGA, transposition of the great arteries.

* Rise in potassium or creatinine levels (>5.5 mmol/L or >231 μmol/L, respectively), symptomatic hypotension and/or symptoms /signs of decompensation.
Materials

The blood pressure monitor (Connect, Wi-Fi Smart Blood Pressure Monitor), step counter (Move, activity and sleep watch), and weight scale (Body, Weight and BMI Wi-Fi Scale) were from the brand Withings and compatible with the Health Mate app for iOS and Android. The blood pressure monitor is an oscillometric device, not requiring assistance from health-care personnel. The rhythm monitor used was from Alivecor KardiaMobile (mobile single-lead ECG) and was compatible with the Kardia app for iOS and Android (Figure 2). The rhythm monitor generates a single-lead ECG rhythm strip after manual initiation by the patient. All devices used have European Conformity (CE) marking and have been previously clinically validated and/or tested.19–21 A dedicated eHealth team instructed and assisted patients during installation and use of these devices and the corresponding apps. A dedicated email address and telephone number were available for ‘on demand’ assistance.

Figure 2 eHealth devices, including weight scale, blood pressure monitor, step counter, and rhythm monitor

(A) Blood pressure monitor (Withings Wi-Fi Smart Blood Pressure Monitor); (B) weight scale (Withings Body, Weight and BMI Wi-Fi Scale); (C) step counter (Withings Move, activity and sleep watch); and (D) rhythm monitor (Alivecor KardiaMobile).
Treatment and follow-up

The smart technology-based care pathway is summarized in Figure 1. A dedicated email address was made available for low threshold contact for patients during the titration process and follow-up.

After 2 weeks of treatment with the starting dose or after dosage modification, blood pressure, weight, complaints, and laboratory findings (renal function, potassium level) were evaluated in a telephone consultation. Data from telemonitoring devices and laboratory values (blood samples drawn at the local general practitioner’s office) were collected from the hospitals patient information systems (EPD-Vision, Leiden, the Netherlands and Hix, Chipsoft, Amsterdam, the Netherlands). If the medication was well tolerated, the dose of sacubitril/valsartan was increased in a stepwise fashion according to clinical protocol. These steps were repeated until the highest tolerated dose or maximal dose of 97/103 mg was reached. Rise in potassium or creatinine levels (>5.5 mmol/L or >221 μmol/L, respectively), symptomatic hypotension, and/or symptoms or signs of decompensation (e.g. weight gain) were followed by a step-down or termination of treatment.

After 3 and 6 months of treatment with the optimal tolerated dose, blood pressure, weight, symptoms, and laboratory investigations (including haemoglobin levels, kidney function, electrolytes, and NT-pro-BNP) were repeated, followed by a consultation in the hospital.

Outcomes

Feasibility (technical and practical consideration of the pathway making it fit for implementation in daily clinical practice), potential to reduce physical hospital visits, patient adherence and satisfaction, and detection of arrhythmias were measured and evaluated by manual assessment of patient information and a questionnaire.

Patient information was derived through assessment of the electronic patient information systems, distance from home to hospital was assessed using the quickest route as indicated in Google Maps route planning. Minimal one-way travel time was assessed using the quickest travel time by car without traffic in Google Maps. Patients were instructed to measure weight and blood pressure twice a week and were stimulated to wear the step counter daily. Patients were instructed to make a single-lead ECG registration if they experienced palpitations or other rhythm-related symptoms. Data were automatically and safely imported into the electronic patient health record file and were only accessible to the medical team. The single-lead ECGs...
were evaluated by the treating cardiologist and followed-up with a telephone or email contact. Patients were instructed to continue measurements once to twice a week.

Patient satisfaction was assessed by an anonymous questionnaire. Patients were asked to evaluate the use of smart technology in the process of titration of new heart failure medication 3 months after optimal dose. This was done by a self-developed dedicated questionnaire (Supplementary material online) consisting of 19 questions and evaluates feasibility, user satisfaction, usability, and overall rating. The results were anonymized and analysed by the study investigators. The treating physician did not have access to the results of the questionnaire during the study period.

Ethics statement
All tests and procedures performed involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 2013 Helsinki declaration or comparable ethical standards and according to Dutch legislation for handling of personal data.

Consent
Appropriate local scientific board approval was obtained and the need for written informed consent was waived by the institutional medical ethical board. All patients provided consent for registration of their data and publication.

Statistical analysis
All statistical analyses were performed in IBM SPSS version 25. Normally distributed continuous data are displayed as mean ± standard deviation and non-normally distributed continuous data are displayed as median [quartile 1, quartile 3]. Proportions are displayed as numbers (percentages).
Results

Patient characteristics

In total, 24 sRV patients (median age 47 years, 50.0% female) were included in the analysis of the primary outcome (Table 1). Median follow-up time was 17 months [14; 19]. Sixteen patients (66.7%) had TGA corrected with the Mustard or Senning atrial switch procedure, and eight patients (33.3%) had ccTGA. 87.5% had a moderately to severely reduced sRV function. The NYHA functional class was II in 17 patients (70.8%) and class III–IV in 29.2%. The median home-hospital distance was 65 km [28; 121], with a maximal distance of 227 km. Median minimal travel time (one-way trip) was 52 min [29; 93], with a maximal time of 158 min.

Table 1: Patient characteristics at baseline (n = 24)

<table>
<thead>
<tr>
<th>Patient characteristics</th>
<th>Baseline (n = 24)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years) (median [Q1; Q3])</td>
<td>47 [44; 50]</td>
</tr>
<tr>
<td>Female (n, %)</td>
<td>12 (50.0%)</td>
</tr>
<tr>
<td>Anatomy (n, %)</td>
<td></td>
</tr>
<tr>
<td>TGA with atrial switch procedure</td>
<td>16 (66.7%)</td>
</tr>
<tr>
<td>ccTGA</td>
<td>8 (33.3%)</td>
</tr>
<tr>
<td>sRV function (n, %)</td>
<td></td>
</tr>
<tr>
<td>Mildly reduced</td>
<td>3 (12.5%)</td>
</tr>
<tr>
<td>Moderately reduced</td>
<td>16 (66.7%)</td>
</tr>
<tr>
<td>Severely reduced</td>
<td>5 (20.8%)</td>
</tr>
<tr>
<td>Tricuspid regurgitation (n, %)</td>
<td></td>
</tr>
<tr>
<td>Grade I</td>
<td>11 (45.8%)</td>
</tr>
<tr>
<td>Grade II</td>
<td>12 (50.0%)</td>
</tr>
<tr>
<td>Grade III</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Grade IV</td>
<td>1 (4.2%)</td>
</tr>
<tr>
<td>NYHA (n, %)</td>
<td></td>
</tr>
<tr>
<td>NYHA II</td>
<td>17 (70.8%)</td>
</tr>
<tr>
<td>NYHA III–IV</td>
<td>7 (29.2%)</td>
</tr>
<tr>
<td>History of SVT (n, %)</td>
<td>14 (58.3%)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>9 (37.5%)</td>
</tr>
<tr>
<td>Atrial flutter</td>
<td>8 (33.3%)</td>
</tr>
<tr>
<td>Atrial tachycardia</td>
<td>10 (41.7%)</td>
</tr>
<tr>
<td>AVNRT</td>
<td>4 (16.7%)</td>
</tr>
<tr>
<td>SVT ablation (n, %)</td>
<td>10 (41.7%)</td>
</tr>
<tr>
<td>Pacemaker/ICD (n, %)</td>
<td>13 (54.2%)</td>
</tr>
<tr>
<td>Distance to hospital (km) (median [Q1; Q3])</td>
<td>65 [28; 121]</td>
</tr>
</tbody>
</table>

AVNRT, atrioventricular nodal re-entrant tachycardia; ccTGA, congenital corrected transposition of the great arteries; ICD, implantable cardioverter-defibrillator; NYHA, New York Heart Association Functional Classification; Q1, quartile 1; Q3, quartile 3; sRV, systemic right ventricle; SVT, supraventricular tachycardia; TGA, transposition of the great arteries.
Titration process and feasibility

Of all 24 patients, 12 (50.0%) had two contact moments for the titration of the medication before the final dose was achieved. In the other patients, a maximum of five contact moments was required to titrate to the maximum tolerated dose. This saved a total of 68 trips to the hospital compared with the conventional outpatient clinic titration process. Thirteen patients (54.1%) could be titrated to the maximal dose of sacubitril/valsartan (97/103 mg). No episodes of hyperkalaemia or deterioration of renal function were observed. One patient (4.2%) discontinued sacubitril/valsartan treatment 2 months after initiation. Other patients (n = 10, 41.7%) did not reach the maximal dose due to (symptomatic) hypotension.

Patient adherence and experience

Of 24 patients, 83.3% of patients submitted measurements twice a week during the titration process. All patients (100%) submitted measurements prior to visits as requested. After titration, 50.0% continued weekly measurements and 70.8% continued (at least) monthly measurements. Twelve patients (50.0%) wore the step counter daily. On average, patients took 429 ± 1976 steps a day. Twenty-two patients completed the eHealth questionnaire (response rate 91.7%, Figures 3 and 4).
Figure 3: Outcome questionnaire patient experience (n = 22).
(A) General patient satisfaction.
(B) Patient empowerment.
(C) Experience titration process.

Figure 4: Outcome questionnaire assessment of usability (n = 22).
Patient satisfaction
Twenty-one patients (95.5%) expressed satisfaction with the smart technology intervention. All patients would recommend the smart technology intervention to others. Nineteen patients (86.4%) considered the smart technology intervention to be of a continued added value after titration and 15 (68.2%) thought it improved their communication with the cardiologist (Figure 3A).

Patient empowerment
The smart technology intervention made 59.1% (n = 13) of the patients feel more secure and 22.7% (n = 5) of the patients more nervous. Nineteen patients (86.4%) looked at and paid attention to their own measurements and 18 (81.8%) would continue even if the cardiologist would not look at the measurements (Figure 3B).

Titration process
All patients considered the smart technology intervention of value during the titration process, most (86.4%, n = 19) did not think it was too time-consuming. None of the patients thought the cardiologist reached out to them unnecessarily because of the measurements (Figure 3C). Fourteen patients (63.6%) found this the best way for the titration of medication, while four patients would have preferred a different way of titration. Two patients (8.3%) would have preferred titration through physical outpatient visits, one (4.2%) patient would have preferred titration through the general practitioner’s office, and one other (4.2%) would have preferred a combination of both smart technology and physical visits.

Usability
Twenty-one (95.5%) patients thought that the blood pressure monitor, scale, and Healthmate App were easy to use and 86.4% considered the step counter to be easy in use. The rhythm monitor and Kardia App was considered easy to use by 54.5% (36.4% missing), and 59.1% (31.8% missing), respectively (Figure 4).

Heart failure
After the titration to the highest tolerated dose, there was a total of 30 contact moments by telephone or email in six patients (25%) in response to home measurements and symptoms, resulting in adjustment of heart failure medication.

One patient discontinued treatment of sacubitril/valsartan and measurements through telemonitoring after a heart failure-related admission. Despite the patient having sent in measurements and repeated contact moments with the treatment team due to congestion-related symptoms and subsequent ambulant medication adjustments,
heart failure-related admission was not prevented. (n = 1, 4.2%). No other heart failure-
related admissions were observed during the study period.

Detection of arrhythmia
A total of 14 patients (58.3%) had a history of supraventricular arrhythmia’s, 12 patients
experienced more than one arrhythmia. Nine patients (37.5%) had a history of atrial
fibrillation, 8 (33.3%) of atrial flutter, 10 (41.7%) of atrial tachycardia, and 4 (16.7%) of
atrioventricular (AV) nodal re-entry tachycardia. In total, 10 patients (41.7%) had
undergone at least one ablation procedure of a supraventricular arrhythmia prior to the
study period.

Five patients (20.8%) sent in a single-lead ECG registration using the provided smart
technology rhythm monitor (Figure 5). One patient sent in an ECG due to chest
discomfort, all other registrations were made due to palpitations. All patients who sent
in an ECG due to palpitation symptoms had a history of supraventricular arrhythmias.
Of the 17 single-lead ECG registrations made during complaints, 13 (76.5%) showed sinus
rhythm, consequently reassuring the patients and potentially saving a trip to the
emergency department or general practitioner’s office. Four registrations (23.5%)
showed a supraventricular arrhythmia, of which one was an atrial flutter with
alternating conductivity, and the three other ones were atrial tachycardias. These
registrations resulted in three admissions for electrical cardioversion, one patient was
already listed for electrophysiological study and ablation and decided not to present to
healthcare services awaiting the already planned procedure. Classification of the exact
type of supraventricular arrhythmia was done at admission based on a 12-lead ECG.
Although the single-lead ECG registration provides information on the frequency and
regularity and can help differentiate between supraventricular and ventricular origin of an
arrhythmia, it has not been validated to diagnose the exact type of arrhythmia in a
patient group with complex anatomy and intrathoracic cardiac position. No cases of
novel arrhythmias were diagnosed through the smart technology rhythm monitor.
Figure 5: Detection of arrhythmia during 6 months of follow-up. ECG, electrocardiogram; SVT, supraventricular tachycardia.

Discussion
This is, to the best of our knowledge, the first study assessing feasibility of telemonitoring and titration of heart failure medication in adult patients with a failing systemic right ventricle in a biventricular circulation. The main findings of this study are:
1. eHealth can be effectively implemented as a part of a clinical care pathway to support medication optimization and titration in this patient group;
2. patient adherence and satisfaction is high; and
3. eHealth can be of potential value in the assessment of arrhythmias and avoiding unnecessary utilization of (emergency) health-care resources in this patient group.

Current results in light of previous studies
A review by Treskes et al. showed that studies on telemedicine solutions for medication adherence are conflicting in the general population, yet a recent pilot study showed that symptomatic CHD patients are suitable and highly motivated for eHealth implementation. Kauw and colleagues also reported promising results of eHealth used for telemonitoring in the CHD population. Although several randomized controlled trials in acquired heart failure showed no benefit of eHealth in comparison to regular healthcare or treatment, eHealth was found feasible with a positive tendency to reduce readmissions and contacts with the treatment team. Prospective studies on the use of eHealth and telemonitoring in CHD patients reported high adherence rates (97% and >70%, respectively) and patient satisfaction (84%), comparable to the results in the current patient group. This can be explained by the high digital literacy of relatively young patients.
young adult CHD patients.\textsuperscript{9} The results of this study therefore corroborate findings of previous studies regarding feasibility of eHealth in adult CHD (ACHD) patients. Based on the literature and the results of this study, specific patient eligibility characteristics for effective remote monitoring can be defined (Table 2). To avoid ‘data overload’,\textsuperscript{24} we suggest that eHealth is used with an approach integrated into a care pathway tailored to specific predefined ACHD patient groups.

### Table 2: Patient eligibility characteristics for complete remote monitoring

<table>
<thead>
<tr>
<th>Patients who can be managed remotely</th>
<th>Patients who require hospital visits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Language proficiency in Dutch/English</td>
<td>Not fulfilling any of the criteria listed in the left column</td>
</tr>
<tr>
<td>Digital literacy</td>
<td>Episodes of congestion during titration process that require hospitalization</td>
</tr>
<tr>
<td>Adequate Wifi connection</td>
<td>(Near-) syncopal arrhythmia</td>
</tr>
<tr>
<td>Possession of a smart phone device</td>
<td></td>
</tr>
<tr>
<td>Commitment and personal motivation to perform structural measurements in a timely manner</td>
<td></td>
</tr>
<tr>
<td>No episodes of congestion/ deterioration of heart failure that would require hospitalization</td>
<td></td>
</tr>
</tbody>
</table>

**Optimization of medication**

Titration of medication in sRV patient population can be challenging due to relatively low baseline blood pressures and poorly understood mechanism of action of heart failure medication in this group, combined with a busy lifestyle with work and personal commitments of these often relatively young patients, and long travel distance to expert clinical centres. By means of structural monitoring of the telemonitoring data and a dedicated email address for low threshold contact, it was possible to rapidly and accurately adjust heart failure medication during titration and follow-up. Several studies and case series on the effects of sacubitril/valsartan in ACHD patients are published to date.\textsuperscript{17,25–27} Although sacubitril/valsartan was generally well tolerated, Maurer et al. did see a reduction in systolic and diastolic blood pressure and a deterioration of renal function, suggesting close monitoring during titration is essential. Our results suggest that eHealth guided titration process is feasible and is of additional value in this young patient group, saving 68 potential outpatient clinic visits.
This way of titration was also positively valued by the patients, as 63.6% found this to be the best way for titration. It also allowed for swift therapy changes to be made as a result of telemonitoring measurements in a substantial number of patients (25%).

Arrhythmia detection
Patients with an sRV in a biventricular circulation are prone to arrhythmias, which are a substantial cause of emergency department presentations and morbidity in this patient group. We report a high prevalence of atrial arrhythmias in our study population (58.3%). The failing sRV is prone to further deterioration during atrial tachycardia and arrhythmias are a potential cause of sudden cardiac death in these patients. This makes early detection and aggressive treatment of these arrhythmias of great importance. In our population, 10 out of 14 patients with known supraventricular arrhythmias had a history of ablation procedures. Telemonitoring has previously been shown to successfully detect supraventricular arrhythmias, and atrial fibrillation in particular. Our data furthermore show that rhythm registrations obtained through the smart technology care pathway were predominantly normal sinus rhythm registrations, showing no arrhythmia (76.5%). These data are in line with previous work of Kauw et al., who reported 55% of rhythm registrations performed by 80 CHD patients to show sinus rhythm. This reflects on the high patient awareness of potential tachyarrhythmias and the ability of this technology to create remote patient assurance, self-management, and empowerment, and prevention of unnecessary emergency healthcare utilization.

COVID-19 pandemic
Although the COVID-19 pandemic was beyond the scope of this study, it clearly demonstrated the need of non-contact care delivery and self- and telemonitoring of symptomatic patients. Especially, in this vulnerable patient population, it is absolutely necessary to curtail hospital visits to avoid potential infections. Due to the COVID-19 pandemic, telemonitoring through smart technology has been rapidly and widely implemented as the ‘new healthcare standard’ allowing for the provision of the right care for the right patient at the right place. This study illustrates that if embedded in a regulated care pathway, eHealth can play an important role in care for ACHD patients in the 21st century.

Study limitations
This study is limited by its single-arm, non-blinded design, and the small study population. Although this is reflective of the rarity of the condition and the inability to blind patients for performing eHealth measurements, the findings reported should be interpreted taking into account the open nature of the study. Another limitation is the
lack of internationally validated questionnaires to assess patient satisfaction of eHealth. Ideally, results should be confirmed in a larger, randomized multicentre trial setting.

**Conclusion**

These data suggest that implementation of a smart technology-based care pathway for optimization of medical treatment for sRV failure is feasible with high measurement adherence and patient satisfaction. If implemented as a part of a regulated care pathway, eHealth has potential in improving healthcare and patient empowerment in the field of ACHD.
References


De magenta omlining geeft de net to maat aan en zal niet zichtbaar zijn in het eindproduct.

Let op: Dit proefbestand is niet geschikt om correcties in te maken.